Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT Pivotal 1: Tofacitinib in moderate to severe chronic plaque psoriasis
NCT01276639Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib oral solution in plaque psoriasis (3 arms), sponsored by Pfizer. Primary endpoints: Physician Global Assessment Response ('Clear' or 'Almost Clear') at 16 weeks and Psoriasis Area and Severity Index 75 Response at 16 weeks. Started Mar 2011; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01276639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01276639.